We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.07%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.23B
AUM Growth
+$191M
Cap. Flow
+$102M
Cap. Flow %
8.28%
Top 10 Hldgs %
30.7%
Holding
101
New
8
Increased
39
Reduced
39
Closed
6

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$18.2M
2
EXAS
Exact Sciences
EXAS
+$18.1M
3
MDT icon
Medtronic
MDT
+$13.5M
4
NVO
Novo Nordisk
NVO
+$13.3M
5
APLS
Apellis Pharmaceuticals
APLS
+$11.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$18.9M
2
UNH icon
UnitedHealth
UNH
+$18.4M
3
CI icon
Cigna
CI
+$11.2M
4
OSCR icon
Oscar Health
OSCR
+$9.64M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.15M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$69.5B
$49.4M 4.01%
590,000
-5,000
-0.8% -$394K
UNH icon
2
UnitedHealth
UNH
$376B
$42.5M 3.45%
72,700
-32,600
-31% -$18.4M
LLY icon
3
Eli Lilly
LLY
$1.02T
$42.1M 3.42%
47,500
+500
+1% +$450K
REGN icon
4
Regeneron Pharmaceuticals
REGN
$78.5B
$41M 3.33%
39,000
+7,000
+22% +$7.79M
THC icon
5
Tenet Healthcare
THC
$20.5B
$36.8M 2.99%
221,400
-7,600
-3% -$1.15M
PRCT icon
6
Procept Biorobotics
PRCT
$1.06B
$35.7M 2.89%
445,000
+5,000
+1% +$355K
ABBV icon
7
AbbVie
ABBV
$443B
$35M 2.84%
177,000
-12,000
-6% -$2.24M
MDT icon
8
Medtronic
MDT
$109B
$33.1M 2.69%
368,000
+160,000
+77% +$13.5M
EXAS
9
DELISTED
Exact Sciences
EXAS
$31.7M 2.57%
465,000
+320,000
+221% +$18.1M
HCA icon
10
HCA Healthcare
HCA
$87.2B
$31M 2.51%
76,229
-5,771
-7% -$2.11M
ISRG icon
11
Intuitive Surgical
ISRG
$127B
$31M 2.51%
63,000
+2,500
+4% +$1.16M
GILD icon
12
Gilead Sciences
GILD
$162B
$30.7M 2.49%
366,500
+128,000
+54% +$9.77M
NTRA icon
13
Natera
NTRA
$38.3B
$29.3M 2.38%
231,000
+74,000
+47% +$8.5M
OSCR icon
14
Oscar Health
OSCR
$9.41B
$29.1M 2.36%
1,371,147
-535,464
-28% -$9.64M
MRK icon
15
Merck
MRK
$322B
$27.4M 2.22%
241,000
+66,000
+38% +$7.84M
BDX icon
16
Becton Dickinson
BDX
$45.6B
$27.1M 2.2%
112,500
-500
-0.4% -$117K
ELV icon
17
Elevance Health
ELV
$81.5B
$26.3M 2.13%
50,500
-35,300
-41% -$18.9M
INSP icon
18
Inspire Medical Systems
INSP
$1.45B
$25.7M 2.09%
122,000
+105,000
+618% +$18.2M
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.6B
$25.6M 2.08%
364,500
+113,000
+45% +$9.45M
COO icon
20
Cooper Companies
COO
$14.1B
$25.2M 2.04%
228,000
-82,000
-26% -$7.98M
ALHC icon
21
Alignment Healthcare
ALHC
$3.08B
$23.4M 1.9%
1,977,363
+335,915
+20% +$3.18M
DHR icon
22
Danaher
DHR
$137B
$23.2M 1.88%
83,302
+34,802
+72% +$9.21M
VRTX icon
23
Vertex Pharmaceuticals
VRTX
$121B
$22.2M 1.8%
47,750
-6,250
-12% -$3M
RPRX icon
24
Royalty Pharma
RPRX
$25.9B
$17.4M 1.41%
613,500
+68,803
+13% +$1.91M
TMO icon
25
Thermo Fisher Scientific
TMO
$213B
$15.5M 1.26%
25,100
+1,100
+5% +$651K
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rhenman & Partners Asset Management held 101 positions worth $1.23B, up 18% from $1.04B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $102M of net new capital in Q3 2024, opening 8 new positions and adding to 39 existing holdings. Its largest new stake was Novo Nordisk: 100,000 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Elevance Health, an estimated $18.9M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2024 buy was Novo Nordisk: 100,000 shares worth $11.9M.
  • Rhenman & Partners Asset Management added most to Inspire Medical Systems in Q3 2024, an estimated $18.2M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2024 reduction was Elevance Health, cutting an estimated $18.9M.
  • Rhenman & Partners Asset Management fully exited Edwards Lifesciences in Q3 2024, selling an estimated $9.01M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.23B portfolio in Q3 2024.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 6 in Q3 2024.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.23B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.